Product Description
A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, cardiovascular and cerebral circulation, brain, thyroid, and joints. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Pertechnetate)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Estonia | Finland | France | Greece | Hong Kong | Hungary | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Netherlands | Norway | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Peking University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Other
Phase 3: Bone Cancer
Phase 2: Pneumonia|COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| SOLLID | N/A |
Completed |
Other |
2022-06-30 |
2023-06-28 |
Primary Endpoints|Start Date |
|
| 99mTC thyroid scan in DTC | N/A |
Unknown status |
Thyroid Cancer |
2021-12-31 |
2023-02-03 |
Primary Endpoints|Treatments|Trial Status |
|
| RISA-19-01 | N/A |
Unknown status |
Other |
2020-04-01 |
2021-10-02 |
Primary Endpoints|Treatments|Trial Status |
|
| USM/JEPeM/19040249 | N/A |
Completed |
Dyspepsia |
2020-02-27 |
2024-11-06 |
Primary Endpoints|Treatments |
|
| RNT COVID-19 | P2 |
Completed |
COVID-19|Pneumonia |
2021-02-10 |
2021-07-08 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
| NA 99Mo 001 | P3 |
Terminated |
Bone Cancer |
2016-11-01 |
2019-03-21 |
Treatments |
|
| 2024-518974-15-01 | P4 |
Not yet recruiting |
Other |
2030-05-15 |
2025-05-02 |
Treatments |
|
| 2021-006371-42 | P4 |
Unknown status |
Unknown |
2027-01-18 |
2025-06-27 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/06/2025 |
News Article |
Lantheus Announces Sale of SPECT Business to SHINE Technologies |
|
10/02/2023 |
News Article |
Steel Gas Spring Market to Boost the Growth during the Forecast Period 2023-2029 |
|
09/21/2023 |
News Article |
Paediatric Sports Medicine Market Growth and Industry Insight 2023 to 2030 |
|
09/18/2023 |
News Article |
Pressure Pumping Market Size, Share & Growth Report, 2030 |